Common TitleGS-366-1216
Official Title A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Phase Phase IIIB
ClinicalTrials.gov NCT02345252
Treatments
Rilpivirine-Tenofovir alafenamide-Emtricitabine

Rilpivirine-Tenofovir alafenamide-Emtricitabine
Tradename:OdefseyOther Names:RPV-TAF-FTCClass:Single-Tablet RegimensFunding
IndustryGilead Sciences